Malignant pleural mesothelioma is a deadly cancer mainly caused by asbestos exposure. It is a hard-to-treat cancer due to its aggressiveness. The cancer affects the pleura, which is the membrane that covers the lungs. A trial known as MARS 2 tried to find out if extended pleurectomy and decortication could[…]
Mesothelioma
The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural Mesothelioma (FAPI-PM)
Primary Outcome Measures Calculate the proportion of patients where the location of the intended pleural biopsy is altered due to FAPI PET/CT replacing FDG PET/CT. Secondary Outcome Measures Compare the cancer stage (IASCL 9th edition TNM-classification) as determined by FAPI PET/CT compared to conventional imaging (including FDG PET/CT) at primary[…]
Improving Mesothelioma Diagnosis
Malignant mesothelioma, an aggressive cancer mainly caused by asbestos exposure, mostly affects the pleura. The pleura is the membrane that surrounds the lungs. It can also harm tissues like the peritoneum, which is a membrane that surrounds the abdomen. Due to its rare nature and shared symptoms with other illnesses,[…]
Changing Gut Bacteria Could Improve Effectiveness of Certain Treatments for Mesothelioma
A new cancer study has found that certain gut bacteria could influence a person’s immune system when fighting mesothelioma, an aggressive cancer of the linings of certain areas of the body including the lungs, abdomen, heart, and testicles. This has led experts to believe that in future cases of mesothelioma,[…]
New Blood Test for Mesothelioma
Mayo Clinic researchers have created a new blood test that is better able to detect mesothelioma. The result could be earlier diagnoses. It could also lead to new options for targeted therapies. The test works by finding complex DNA patterns that are common in mesothelioma cells. The new approach is[…]
Keytruda and Chemotherapy Approved for the Treatment of Mesothelioma
A new first line treatment was approved by the U.S. Food and Drug Administration for the treatment of pleural mesothelioma that cannot be removed by surgery. The approval is specifically for Keytruda alongside pemetrexed and platinum chemotherapy. The approval follows the promising results in phases 2 and 3 of the[…]
Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors
This is a Phase 1, open-label, multicenter, FIH study to evaluate the safety, tolerability, recommended Phase 2 dose (RP2D), PK/PD, and preliminary anti-tumor activity of ISM6331 in participants with advanced or metastatic malignant mesothelioma or other solid tumors. The study consists of two parts, a dose escalation part (Part 1) and a dose selection optimization part (Part 2).
CAR-T Cell Therapy for Mesothelioma
Mesothelioma is a rare, yet aggressive cancer mainly caused by asbestos exposure. There are very limited options for treatment. This is especially true for elderly patients. Conventional therapies might not be the best option due to the person’s age and other health problems. Chimeric antigen receptor (CAR) T cell therapy[…]
Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM
To explore the efficacy and safety of sintilimab, bevacizumab combined with pemetrexed and cisplatin in the treatment of malignant peritoneal mesothelioma, and to explore the biomarkers related to efficacy or safety.
New Preclinical and Clinical Approaches to Mesothelioma
This study protocol involves the coordination between UO1 (IRCCS San Raffaele Hospital) and UO2 (Istituto Nazionale Tumori di Napoli – IRCCS G. Pascale) to explore the role of HMGB1 and CXCR4 in cancer treatment and metastasis. UO1 focuses on the role of HMGB1 in inflammation, mesothelioma progression, and tissue repair, as well as developing, in future, possible HMGB1 inhibitors for cancer therapy. UO2 specializes in CXCR4’s role in cancer, developing CXCR4 antagonists, and tracking CXCR4-dependent metastasis. The hypothesis is that targeting HMGB1 and CXCR4 pathways will inhibit tumor progression and metastasis, enhancing anti-tumor immunity and improving therapeutic outcomes in cancer.
